Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

Epstein-Barr virus (EBV) is a fascinating microorganism, as a "double-facetted" viral agent. After primary infection, it can persist throughout a person's lifetime in a latent form, from which it can reactivate following specific stimuli (i.e., immunodepression). Unlike other herpesviruses, EBV reactivates a countless number of times with such a high replication rate that it is unable to be controlled by conventional anti-herpesvirus drugs. Moreover, for various reasons, no vaccine is currently available in the market. This book presents a comprehensive overview of EBV, including information on its potential for oncogenic activity, its various isolates, and possible vaccine candidates.

Epstein-Barr virus diseases.

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

Annotation

Oncogenic viruses. --- Tumors --- Virus diseases. --- Epstein-Barr virus diseases. --- Kaposi's sarcoma. --- Papillomaviruses. --- Virology.

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

This Special Issue on CFS/ME collects 18 papers with an interdisciplinary view on the current demographic and epidemiological data and immunological characteristics of CFS/ME and examines the different pathogenic hypotheses, as well as giving information about the latest knowledge on diagnostic investigations, pharmacological, integrative, physical, cognitive-behavioral and psychological curative approaches.

Chronic fatigue syndrome. --- Chronic fatigue and immune dysfunction syndrome --- Chronic fatigue immune dysfunction syndrome --- Diseases --- Fatigue --- Syndromes --- Epstein-Barr virus diseases

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

G-quadruplexes (G4s) are nucleic acids secondary structures that form in DNA or RNA guanine (G)-rich strands. In recent years, the presence of G4s in microorganisms has attracted increasing interest. In prokaryotes, G4 sequences have been reported in several human pathogens. Bacterial enzymes able to process G4s have been identified. In viruses, G4s have been suggested to be involved in key steps of the viral life cycle: They have been associated with the human immunodeficiency virus (HIV), herpes simplex virus 1 (HSV-1), human papilloma virus, swine pseudorabies virus, and other viruses’ genomes. New evidence shows the presence of G4s in parasitic protozoa, such as the causative agent of malaria. G4 binding proteins and mRNA G4s have been implicated in the regulation of microorganisms’ genome replication and translation. G4 ligands have been developed and tested both as tools to study the complexity of G4-mediated mechanisms in the viral life cycle and as therapeutic agents. Moreover, new techniques to study G4 folding and their interactions with proteins have been developed. This Special Issue will focus on G4s present in microorganisms, addressing all the above aspects.

bacteria --- folding --- co-translational refolding --- RecQ helicase --- regulatory element --- conformational dynamics --- G4Hunter --- NDPK --- fluorescence --- pseudorabies virus --- Epstein-Barr virus (EBV) --- structure-activity relationship --- PhenDC3 --- eukaryotic hosts --- Herpesvirus --- translation suppression --- turn-on ligands --- co-transcriptional folding --- Herpesviridae --- G-quadruplex --- nucleoside diphosphate kinase --- nucleic acids --- nucleic acids conformation --- bioinformatics --- protein–DNA interaction --- aptamers --- deinococcus --- Alphaherpesvirinae --- EBNA1 --- G4 --- virus --- human papillomaviruses --- S. cerevisiae --- genome stability --- G-quadruplexes --- metastable structure --- genome evolution --- pyridostatin --- alphaherpesviruses --- structure --- protozoa --- genome --- G-quadruplex ligand --- NMR --- microbes --- DNA --- protein-mRNA interactions --- G-quadruplex formation --- immediate early promoters

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

Antiviral agents are used for the treatment of viral diseases. Antiviral drugs have been successfully developed and used clinically for a limited number of important human viral diseases notably caused by human immunodeficiency virus (HIV), hepatitis C virus (HCV), hepatitis B virus (HBV), herpes, and influenza viruses. Despite the successes of these antiviral drugs, issues with drug resistance and toxicity remain challenging. These challenges are driving research to identify new drug candidates and to investigate novel drug targets to develop new mechanistic drug classes. Antiviral agents are not available against many viruses that cause human disease and economic burdens; in particular, the development of antiviral agents against emerging, re-emerging, and neglected viruses is increasingly becoming a priority. This book includes six review articles that discuss new antiviral strategies. The reviews either discuss advances relating to a specific virus or new therapeutic targets and approaches. The book includes 15 original research articles reporting new antiviral agents against a variety of clinically and economically important viruses and studies into the prevalence or acquisition of drug resistance. Overall, this book is an exciting collection of new research and ideas relating to the development of antiviral agents.

Zika virus --- nucleoside analogues --- antiviral agents --- NS5 --- prodrugs --- ProTides --- neural stem cells --- RNA-dependent RNA polymerase --- cytomegalovirus --- latent infection --- TALEN --- Surveyor nuclease mutation detection assay --- ie-1 gene --- quantitative real-time PCR --- Epstein–Barr virus --- herpes viruses --- lytic gene expression --- Burkitt lymphoma cells --- clozapine --- antipsychotic drug --- antiviral drug --- enteroviruses --- coxsackievirus B4 --- persistent infection --- fluoxetine --- resistance --- mutations --- herpes B virus --- macacine herpesvirus-1 --- genistein --- flavonoids --- acyclovir --- ganciclovir --- Plantago asiatica --- Clerodendrum trichotomum --- RSV --- therapeutic effects --- acteoside --- human antimicrobial peptides --- antiviral strategies --- defensins --- cathelicidins --- hepcidins --- transferrins --- influenza A virus --- brevilin A --- antiviral --- sesquiterpene lactone --- replication --- PRRSV --- polyethylenimine --- PEI --- virion internalization --- endocytosis --- HIV --- pediatrics --- Ethiopia --- pre-treatment drug resistance --- combination antiretroviral therapy (cART) --- dried plasma spots --- dried blood spots --- sphingolipids --- glycosphingolipids --- viruses --- lipid biosynthesis --- flavivirus --- Japanese encephalitis virus --- furin inhibitor --- precursor membrane protein --- measles virus --- central nervous system --- tropism --- treatments --- porcine reproductive and respiratory syndrome virus --- ginsenoside Rg1 --- antiviral activity --- pro-inflammatory factor --- NF-κB signaling pathway --- acute/latent infection --- congenital infection --- antiviral agent --- therapeutic strategies --- nucleic acid-based therapeutic approach --- HCMV vaccine --- adoptive cell therapy --- Rev response element --- chemical footprinting --- SHAPE --- drug discovery --- branched peptides --- herpesvirus --- immediate-early --- IE1 --- IE2 --- ribozyme --- RNA interference --- CRISPR/Cas --- small molecule --- orthohantavirus --- phenyl-benzotriazoles --- C-FRA --- Porcine circovirus type 2 --- epigallocatechin gallate --- heparan sulfate --- antiviral effect --- virus attachment --- microvirin --- lectin --- human immunodeficiency virus --- hepatitis C virus --- antiviral inhibitor --- non-immunogenic --- viral entry --- protein drugs --- LUMS1 --- oleanane-type derivatives --- influenza A virus (IAV) --- virus entry inhibitors --- hemagglutinin (HA) --- n/a --- Epstein-Barr virus